The seroprevalence of SARS-CoV-2 in patients on haemodialysis
- PMID: 33230249
- PMCID: PMC7682124
- DOI: 10.1038/s41581-020-00379-y
The seroprevalence of SARS-CoV-2 in patients on haemodialysis
Abstract
A new study reports the seroprevalence of SARS-CoV-2 antibodies among a cross-section of patients on haemodialysis and uses these data to estimate seroprevalence in the general US population. Although this study demonstrates the potential of monitoring infectious disease prevalence in dialysis populations, the findings should be interpreted with caution.
Conflict of interest statement
The authors declare no competing interests.
Comment on
-
Prevalence of SARS-CoV-2 antibodies in a large nationwide sample of patients on dialysis in the USA: a cross-sectional study.Lancet. 2020 Oct 24;396(10259):1335-1344. doi: 10.1016/S0140-6736(20)32009-2. Epub 2020 Sep 25. Lancet. 2020. PMID: 32987007 Free PMC article.
References
-
- Hiremath, S. et al. Dialysis and CKD-summary of mortality from COVID-19 among dialysis patients. #NephJChttp://www.nephjc.com/news/2020/3/23/covid-and-the-kidney-dialysis-edition (2020).
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous